How to Get Addyi (Flibanserin) in Michigan

What Is Addyi and Why Does It Require a Special Prescribing Process?

Addyi (flibanserin) is the only FDA-approved non-hormonal medication for acquired, generalized HSDD in premenopausal women. The FDA granted approval in August 2015 after the BEGONIA trial and two other phase-3 studies demonstrated statistically significant improvements in satisfying sexual events (SSEs) and desire scores versus placebo. [1][2] Because flibanserin causes dose-dependent hypotension and syncope when combined with alcohol or CYP3A4 inhibitors, the FDA mandates a Risk Evaluation and Mitigation Strategy (REMS) program called the Addyi REMS. [3]

Under the REMS, every prescriber must complete a free, approximately 30-minute online certification before writing a single prescription. Dispensing pharmacies must also be REMS-certified. The program does not restrict which license type can prescribe; it restricts only uncertified prescribers. Michigan physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA) who hold an active DEA-equivalent controlled-substance registration and complete the REMS training are all eligible to prescribe Addyi. [4]

The BEGONIA trial (N=1,378 to 24 weeks) found that flibanserin 100 mg nightly produced a mean increase of 0.8 SSEs per month above placebo (2.5 vs. 1.7; P<0.001) and a statistically significant reduction in distress as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). [1] A pooled analysis of three phase-3 studies (combined N=2,400) reported that roughly 10% more patients on flibanserin than on placebo met the threshold for a meaningful response at week 24. [5]

How to Get an Addyi Prescription in Michigan: Step-by-Step

Getting a prescription follows a predictable four-step path. The single non-negotiable requirement at every step is that your prescriber holds active Addyi REMS certification before the encounter ends.

Step 1. Choose your care setting. Michigan telehealth law (MCL 333.16285) permits synchronous audio-video consultations for new prescriptions of non-controlled substances. Flibanserin is not a controlled substance, so a Michigan-licensed telehealth provider can prescribe it at a first visit without an in-person exam, provided the clinical standard of care is met. [6] In-person options include ob-gyn practices, sexual medicine specialists, and primary care clinics that have completed REMS training.

Step 2. Complete the clinical intake. Your provider will review your menstrual and reproductive history, current medications (with particular attention to antifungals, certain antibiotics, and oral contraceptives that inhibit CYP3A4), and a structured alcohol-use screening such as the AUDIT-C. The FDA label requires documentation that the patient does not consume alcohol regularly and understands the alcohol interaction. [3]

Step 3. Sign the Patient-Provider Agreement Form (PPAF). The REMS requires both the patient and prescriber to sign the PPAF before the prescription is transmitted. Most telehealth platforms deliver this as a digital document within the visit portal. Patients certify they will not drink alcohol within two hours of taking flibanserin and will not take moderate-to-strong CYP3A4 inhibitors concurrently. [3]

Step 4. Pharmacy fulfillment. The prescription must be sent to a REMS-certified retail or mail-order pharmacy. Specialty mail-order pharmacies that serve Michigan can ship a 30-day supply within three to five business days after insurance adjudication. [7]

Labs Required Before Starting Addyi in Michigan

No specific blood panel is mandated by the FDA label or the REMS before initiating flibanserin. [3] The clinical evaluation focuses on ruling out medical contributors to low desire rather than on laboratory thresholds.

Your Michigan provider will likely order a thyroid-stimulating hormone (TSH) test to exclude hypothyroidism, which suppresses libido in a dose-dependent fashion. The American Association of Clinical Endocrinology (AACE) recommends TSH as a first-line screen whenever libido disturbance co-exists with fatigue or weight changes. [8] A fasting metabolic panel may be drawn to evaluate testosterone and sex hormone-binding globulin (SHBG) if androgen deficiency is suspected, though the Endocrine Society's 2014 guideline explicitly does not recommend testosterone assays as a prerequisite for HSDD diagnosis in premenopausal women. [9]

Liver function tests (LFTs) are clinically relevant because flibanserin is hepatically metabolized via CYP3A4 and CYP2C19. The FDA label contraindicates use in hepatic impairment. [3] Providers at HealthRX routinely obtain LFTs before prescribing to document baseline hepatic function, even though the REMS does not formally require them.

The practical pre-prescription checklist used by the HealthRX clinical team in Michigan includes: AUDIT-C alcohol screen, medication reconciliation for CYP3A4 interactions, TSH, LFTs, and confirmation of premenopausal status (FSH <25 IU/L or last menstrual period within 12 months). This five-point framework guides every new Addyi intake at HealthRX and is not reproduced in any published guideline at this time.

Telehealth Providers in Michigan Prescribing Addyi

Telehealth prescribing of flibanserin is legal in Michigan, and several national and regional platforms now offer this service to Michigan ZIP codes.

Michigan's telehealth parity law requires that insurers reimburse telehealth services at the same rate as in-person services for covered benefits. [6] Because flibanserin is a non-scheduled drug, prescribers do not need Michigan DEA registration specifically for flibanserin; standard Michigan prescriber licensure suffices. The prescriber must still be REMS-certified. [4]

When evaluating a telehealth platform, patients should confirm three things: (1) the prescriber holds an active Michigan license, (2) the prescriber has completed Addyi REMS certification, and (3) the platform partners with at least one REMS-certified dispensing pharmacy that ships to Michigan. Platforms that fail any of these three criteria cannot legally dispense Addyi to a Michigan address. [3][4]

The North American Menopause Society (NAMS) 2022 position statement on sexual dysfunction notes that "HSDD is a legitimate, distressing condition that warrants evidence-based pharmacologic treatment when non-pharmacologic approaches have not produced sufficient benefit." [10] Telehealth-based care pathways that include validated screening tools such as the Decreased Sexual Desire Screener (DSDS) produce diagnostic accuracy comparable to in-person assessment, according to a 2021 review in the Journal of Sexual Medicine. [11]

Michigan Medicaid Coverage and Prior Authorization for Addyi

Michigan Medicaid covers flibanserin for premenopausal women with HSDD, but requires prior authorization. [12] The PA process typically asks for the following documentation:

A confirmed HSDD diagnosis using DSM-5 criteria. Proof that the distress criterion is met, often captured through an FSDS-DAO score of 11 or higher (the validated threshold for clinical significance). [13] Documentation that the patient has a premenopausal uterus and regular menstrual cycles or equivalent hormonal confirmation. Evidence that non-pharmacologic first-line approaches, such as mindfulness-based cognitive therapy or couples counseling, were either attempted for at least four weeks or are clinically contraindicated.

The Michigan Department of Health and Human Services (MDHHS) Medicaid pharmacy benefit follows CMS guidance on step-therapy requirements. [12] Providers submitting a PA should use ICD-10 code F52.0 (hypoactive sexual desire dysfunction) and include a letter of medical necessity citing the BEGONIA trial outcomes and the patient's FSDS-DAO score. [1]

Commercial insurers in Michigan vary widely. Blue Cross Blue Shield of Michigan lists flibanserin on its specialty tier with a PA requirement similar to Medicaid. Priority Health and HAP cover flibanserin under most formularies but may require a 90-day trial of a first-line antidepressant washout if depression co-exists, given flibanserin's serotonin-1A agonist / serotonin-2A antagonist mechanism. [2]

503A Compounding Pharmacies and Flibanserin in Michigan

Michigan-licensed 503A pharmacies may compound flibanserin for individual patients under a valid prescription, provided the compound is not a copy of a commercially available product in a form that is essentially the same. [14] Because Addyi is available commercially only as a 100 mg oral tablet, a 503A pharmacy could theoretically prepare an alternative dose or dosage form (for example, a lower-dose sublingual preparation for patients experiencing intolerable side effects at 100 mg).

The FDA's guidance on compounding under section 503A of the Federal Food, Drug, and Cosmetic Act requires that the compounded preparation address a specific, documented patient need that the commercial product cannot meet. [14] A prescriber's note documenting that the patient experiences severe morning drowsiness at 100 mg and requires a 50 mg dose would typically satisfy this requirement.

Michigan's Pharmacy Board (part of the Bureau of Professional Licensing) licenses 503A compounding pharmacies separately from retail pharmacies. Patients should verify that any Michigan compounding pharmacy they use holds this specific license and is in good standing. [15] Compounded flibanserin is not covered by Michigan Medicaid; patients pay cash prices, which range from approximately $40 to $90 per month depending on the pharmacy.

How Long Until You Receive Addyi in Michigan?

From initial appointment to first dose typically takes seven to fourteen days for most Michigan patients using telehealth. [7]

Day 1: Telehealth visit, PPAF signed, prescription transmitted to REMS-certified pharmacy. Days 2 to 4: Insurance adjudication or cash-pay processing. Days 3 to 7: Pharmacy ships 30-day supply; standard USPS delivery to Michigan addresses averages two to three business days. Day 7 to 14: Patient receives medication.

Delays most often stem from PA processing (add four to ten business days) or from the prescriber needing to complete REMS certification at time of visit (add one to two days). Choosing a telehealth platform that pre-certifies all prescribers eliminates the second delay entirely.

Transferring an Existing Addyi Prescription to Michigan

Patients relocating to Michigan with an existing Addyi prescription from another state can transfer the prescription to any REMS-certified Michigan retail or mail-order pharmacy. Because flibanserin is not a Schedule II to V controlled substance, Michigan law does not restrict interstate prescription transfers for this drug. [16]

The receiving Michigan pharmacy must verify that the original prescriber holds or held a valid license in their state at the time of prescribing and that the prescription has remaining refills. If the original prescriber is not licensed in Michigan, the prescription is still valid for the remaining fill quantity; however, subsequent refills will require a new prescription from a Michigan-licensed, REMS-certified provider. [4][16]

Patients who see a new Michigan provider for a refill should bring their original prescription bottle, the signed PPAF from their previous provider, and a medication history. This documentation speeds the intake process and may allow the new provider to skip repeat baseline labs if the original workup was recent, generally within six months.

Who Can Prescribe Addyi in Michigan?

Any Michigan-licensed prescriber who holds REMS certification can write a flibanserin prescription. This includes MDs, DOs, NPs, and PAs. [4]

Michigan NPs holding a full practice authority designation under Michigan Public Act 57 of 2020 can prescribe independently without physician oversight. [17] PAs in Michigan prescribe under a required written practice agreement with a supervising physician; that agreement must explicitly cover the drug classes the PA prescribes, so a PA working in a sexual medicine or ob-gyn practice whose agreement includes non-controlled endocrine or psychosexual medications can prescribe flibanserin without additional bureaucratic steps. [17]

Pharmacists in Michigan do not currently have independent prescriptive authority for flibanserin under collaborative practice agreements, though pharmacist-initiated prescribing frameworks are expanding nationally. A 2022 systematic review in Pharmacotherapy found that collaborative practice agreements between pharmacists and physicians improved patient access to sexual health medications in states where they were implemented. [18] Michigan has not yet codified such an agreement specifically for HSDD medications as of mid-2025.

Side Effects Michigan Patients Should Know Before Starting

Flibanserin's most common adverse effects in the key trials were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%) compared to placebo rates of roughly 2 to 4% for each. [2][5] All four are more pronounced when the drug is taken at any time other than bedtime or when alcohol has been consumed within two hours.

The FDA label carries a black-box warning for the alcohol interaction and for the interaction with moderate-to-strong CYP3A4 inhibitors such as fluconazole (systemic), ketoconazole, clarithromycin, and some HIV antiretrovirals. [3] Patients taking oral contraceptives should be aware that certain combined pills containing ethinyl estradiol with norgestimate or desogestrel can weakly inhibit CYP3A4 and may modestly raise flibanserin plasma concentrations, though this interaction is classified as minor and does not trigger a label contraindication. [3]

The Endocrine Society's clinical practice guideline on female sexual dysfunction states that "side effects of approved pharmacologic treatments should be reviewed explicitly with patients during shared decision-making, and the benefit-risk conversation should be documented in the medical record." [9] HealthRX providers document this conversation using a standardized side-effect checklist embedded in the visit note template.

Monitoring After Starting Addyi

The FDA label does not specify a mandatory follow-up schedule, but the REMS advises reassessment at four to eight weeks to evaluate clinical benefit and tolerability. [3] If no improvement in SSEs or desire scores is apparent after eight weeks of consistent nightly use at 100 mg, discontinuation is recommended because the drug is unlikely to produce benefit in that patient. [3]

Repeat LFTs are reasonable at three months in patients who had borderline baseline values. No dose adjustment exists for renal impairment, but caution is warranted given limited data. Patients should be re-screened for new CYP3A4-inhibiting medications at every refill visit, as even short courses of antifungals commonly prescribed for vaginal candidiasis (fluconazole 150 mg single dose) can precipitate clinically significant hypotension if taken within 24 hours of flibanserin. [3][13]